APPLICATION
Application Note
The peptide is used for blocking the activity of DcR3 (GTX28405). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Tnf Receptor Superfamily Member 6B , Dcr3 , Dj583P15.1.1 , M68 , M68E , Tr6 , Tnfrsf6B
Background
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. Several novel members in the TNFR family including DR3, DR4, DR5, and DR6 were recently discovered and function as cell death receptors. Two decoy receptors, DcR1 and DcR2, were recently identified to compete with DR4 and DR5 for their ligand TRAIL binding. A novel decoy receptor was more recently discovered and designated DcR3 and TR6, respectively. Unlike DcR1and DcR2, DcR3 is a soluble rather than a membraneassociated molecule. DcR3 binds to FasL and LIGHT andinhibits FasL and LIGHT induced apoptosis. DcR3 transcript is expressed in a number of lung and coloncarcinomas and in some normal tissues.
Research Area
REFERENCE
There are currently no references for DcR3 peptide (GTX28437). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for DcR3 peptide (GTX28437). Be the first to share your experience with this product.